Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$59.95 USD

59.95
4,196,031

+1.47 (2.51%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $59.92 -0.03 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ASRT vs. CTLT: Which Stock Is the Better Value Option?

by Zacks Equity Research

ASRT vs. CTLT: Which Stock Is the Better Value Option?

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Catalent (CTLT) Expands Packaging Capabilities at Japan Facility

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.

3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

by Zacks Equity Research

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

Why Is Jazz (JAZZ) Down 1.5% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent (CTLT) Up 0.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent's (CTLT) Latest Facility Expansion to Boost Capacity

by Zacks Equity Research

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Catalent's (CTLT) New Launch to Enhance Gene Therapy Development

by Zacks Equity Research

Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.

Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up

by Zacks Equity Research

Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.

Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 10.64% and 4.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Catalent (CTLT) Ahead of Earnings?

by Zacks Equity Research

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Catalent (CTLT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity

by Zacks Equity Research

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint

by Zacks Equity Research

Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.

Here's Why Catalent (CTLT) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Catalent's (CTLT) New Project Completion Expands Global Footprint

by Zacks Equity Research

Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Catalent's (CTLT) New Tie-Up to Provide Better Patient Access

by Zacks Equity Research

Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.

Catalent (CTLT) Down 3.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.